DUPIXENT® is self-injected by subcutaneous injection and available as a pre-filled syringe and pen1
DUPIXENT® is intended for use under the guidance of a healthcare provider. A patient may self-inject DUPIXENT® or the patient’s caregiver may administer DUPIXENT®. Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT® prior to use, according to the Instructions for Use.1
Recommended dosing for adult patients with CRSwNP is 300 mg every other week.
DUPIXENT® has 3 dosage formats:
300 mg pre-filled syringe with needle shield
DUPIXENT® is provided as a single dose in a 2.25-mL siliconized clear Type-1 glass pre-filled syringe with a fixed 27-gauge ½ inch, thin-wall stainless steel staked needle and passive needle shield.
300 mg pre-filled syringe
DUPIXENT® is provided as a single dose in a 2.25-mL siliconized clear Type-1 glass pre-filled syringe with a fixed 27-gauge ½ inch, thin-wall stainless steel staked needle
300 mg pre-filled pen
A DUPIXENT® administration option for you and your patients
Features of the DUPIXENT® pre-filled pen include:
• Single-dose autoinjector
• Hidden needle
• Audible click when injection starts
• Window to check medicine and injection completion
• Step-by-step instructions for self-injection by subcutaneous injection
The needle cap is not made with natural rubber latex.
Please refer to the Product Monograph for complete dosing and administration instructions.
Preparation for use1
• Before injection, instruct patients and/or caregivers to remove the DUPIXENT® pre-filled syringe or pre-filled pen from
the refrigerator.
• 300 mg pre-filled syringe or pen: allow DUPIXENT® to reach room temperature by waiting 45 minutes.
• Patients and/or caregivers should inspect DUPIXENT® for particulate matter and discoloration prior to administration.
• Patients and/or caregivers should not use the pre-filled syringe/pen if the liquid contains visible particulate matter, or is
discolored or cloudy (other than clear to slightly opalescent, colorless to pale yellow).
• Patients and/or caregivers should discard any unused product remaining in the pre-filled syringe/pen in accordance
with local requirements.
Important administration instructions1
• Patients and/or caregivers should read the Instructions for Use prior to
injecting.
• Instruct patients and/or caregivers to administer subcutaneous
injection into the thigh or abdomen, except for the 2 inches (5 cm)
around the navel.
• The upper arm can also be used if a caregiver administers the injection.
• It is important to rotate the injection site with each injection. DO NOT
inject DUPIXENT® into skin that is tender, damaged, bruised, or scarred.
DO NOT inject through clothes.
• Choose a different injection site for each DUPIXENT® injection. If you
need a second injection to complete your dose then leave at least 5 cm
(2 inches) between the two injection sites.
Invite your patients to watch our injection training videos so they can see how to inject DUPIXENT®.
Storage and Handling1
DUPIXENT® should be refrigerated at 2–8°C, never frozen or exposed to extreme heat
DUPIXENT® is light sensitive, so it should be kept in its carton in order to protect it from light
Do not shake DUPIXENT® or use beyond the expiration date
DUPIXENT® may be kept at room temperature (up to 25°C) for up to 14 days
After removal from the refrigerator, DUPIXENT® must be used within 14 days or discarded.
Connect With a Rep
Have questions about DUPIXENT®? Get answers from a representative.
Freedom Support Program
Find out what the Freedom Support Program can bring to your patients and how you can help them access it.
DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.
MAT-CA-2300229E
Last updated: 06/2023
